Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Ribo Life Science realises series C2 round
SAIC Motor fund Hengxu Investment and a Sinopharm-backed joint venture were among the investors in a $66.3m round for the RNA drug developer.
Pandion packs in $80m
Autoimmune disease drug developer Pandion Therapeutics closed a series B round co-led by Access Biotechnology and backed by Roche Venture Fund and SR One.
Aspen Neuroscience ascends with $70m
The Parkinson's disease therapy developer closed the series A funding less than four months after a Eurofarma-backed seed round.
Affinia affirms $60m series A
Lonza participated in the gene therapy developer's series A round alongside Partners Innovation Fund, having also licensed technology to the startup.
Olive collects $51m
General Catalyst led a $51m round for the Ascension-backed healthcare automation technology developer, which has now received $119m in total.
Daojiale houses funding from and its 58 Aifang subsidiary invested $70.5m and will help the online real estate marketplace expand its services and grow throughout southwestern China.
NextVPU executes series B round
Cethik-backed artificial intelligence chipmaker NextVPU has received $42.3m from unnamed investors to scale its research and development activities.
Kyash gets series C payment
The corporate-backed mobile banking services provider collected $43.6m in a round co-led by Goodwater Capital and Greenspring Associates.

Other News

Huilianyi hauls in series C-plus funding
SoftBank China Venture Capital returned for a $42.3m round that will support the international growth of Huilianyi's expenses management software.
Dremio drops $70m series C funding details
The data management software provider has now secured a total of $115m, Cisco Investments returning to back its latest round.
Nature's Fynd unearths $80m
The edible protein developer has rebranded from Sustainable Bioproducts and received series B funding from investors including existing backers Danone and Archer Daniels Midland.
Abbisko absorbs $70m
Lilly Asia Ventures, an investor in the cancer drug developer since its series A round, returned to back a series C that doubled its overall funding to $140m.
Design Therapeutics draws up $45m series A
SR One led a round disclosed by the genetic medicine developer, a spinout of University of Wisconsin-Madison, as it emerged from stealth.
Sigilon signs off on series B funding
Eli Lilly took part in an $80.3m round that pushed chronic illness drug developer Sigilon Therapeutics' overall funding to nearly $200m.

Editor's Picks

No posts to show.

test reg